The FDA Desk — 2026-04-27

TITLE: FDA Desk — April 27, 2026: Sterile injectables dominate; Teva clonidine patches cited for unapproved raw material

---

Top line

No Class I recalls posted today. The day's enforcement activity centers on two clusters: a sweeping sterility-assurance recall of Fresenius Kabi sodium chloride injection bags, paired Fagron compounded vancomycin lots with the same sterility concern plus a device defect, and a Teva/Actavis clonidine transdermal recall tied to CGMP raw-material deviations. All actions are Class II and firm-initiated.

Class II — Sterile injectable saline (Fresenius Kabi)

• Fresenius Kabi USA initiated a multi-presentation recall of 0.9% and 0.45% Sodium Chloride Injection USP in freeflex bags on 2026-03-11 for lack of assurance of sterility, an enforcement signal that typically reflects a containment or process-validation failure rather than confirmed contamination.
• The affected lots span the company's 100 mL, 250 mL, and 500 mL freeflex configurations, including D-0426-2026 (100 mL 0.9%), D-0427-2026 and D-0428-2026 (250 mL and 500 mL 0.9%), D-0432-2026 (500 mL single-dose 0.9%), and D-0424-2026 (250 mL 0.45%) — covering the bulk of Fresenius Kabi's small-volume saline catalog.
• D-0430-2026 extends the same sterility recall to 100 mL single-dose freeflex bags manufactured by Fresenius Kabi but distributed under the BD (Becton, Dickinson) label — purchasers should treat BD-branded inventory as in-scope.

Class II — Compounded vancomycin (Fagron Sterile Services)

• Fagron Compounding Services recalled two strengths of premixed Vancomycin HCl in 0.9% Sodium Chloride — D-0440-2026 (1.25 g/250 mL, NDC 71266-5083-01) and D-0441-2026 (1.5 g/250 mL, NDC 71266-5085-01) — on 2026-03-20 citing both lack of sterility assurance and a device defect: the blue Break-Off-Part on the administration port may detach.
• The dual-defect posture is notable: a detachable port component is a particulate and dosing-integrity hazard independent of the sterility finding, and pharmacy buyers should pull both lots from automated dispensing cabinets rather than rely on point-of-use inspection.

Class II — Clonidine transdermal system (Teva / Actavis)

• Teva Pharmaceuticals USA recalled both strengths of its Actavis-manufactured Clonidine Transdermal System — D-0472-2026 (0.1 mg/day) and D-0473-2026 (0.2 mg/day), each in 4-system cartons — on 2026-03-19 for CGMP deviations involving use of an unapproved raw material.
• Unapproved-raw-material findings are an FDA quality-system citation rather than a clinical adverse-event recall, but they expose the manufacturer to follow-on 483 observations and potential consent-decree exposure if the deviation reflects a sourcing-control breakdown at the Salt Lake City facility. Prescribers transitioning patients off recalled patches should note clonidine's rebound-hypertension risk on abrupt discontinuation.

Editor's note

Today's docket reinforces a pattern The FDA Desk has tracked across Q1 2026: sterility-assurance recalls — not confirmed contamination events — continue to drive the majority of injectable Class II actions, with Fresenius Kabi and compounders accounting for a disproportionate share. Hospital pharmacy and 340B compliance teams should expect continued saline-supply pressure.